Cáncer (prevención)

27-Deoxyactein is a key triterpene glycoside and active constituent of black cohosh (Cimicifuga racemosa), the most extensively studied botanical for menopausal hot flashes. Its presence is used to standardize black cohosh extracts studied in multiple RCTs demonstrating reductions in vasomotor symptoms.

8-Prenylnaringenin (8-PN) is the most potent known plant-derived phytoestrogen, derived from hops (Humulus lupulus). It has been specifically studied in RCTs for menopausal hot flashes; a combination trial (soy isoflavones + 8-PN + melatonin) demonstrated improved hot flashes in postmenopausal women, though standalone RCT results are conflicting.

Alfalfa is rich in phytoestrogens (coumestrol, formononetin, biochanin A) that bind estrogen receptors and may mitigate vasomotor symptoms. A study combining alfalfa with sage in 30 menopausal women reported reduced hot flashes. Broader Cochrane evidence on phytoestrogens from multiple plants shows modest hot flash reduction.

Multiple recent randomized, double-blind, placebo-controlled trials have assessed standardized A. racemosus (shatavari) root extract for vasomotor symptoms including hot flashes in perimenopausal and menopausal women, with positive results. The mechanism is attributed to phytoestrogenic activity of steroidal saponins (shatavarins) that bind estrogen receptors.

Epimedium prenylflavonoids act as phytoestrogens binding estrogen receptors, providing a plausible mechanism for alleviating vasomotor symptoms like hot flashes in postmenopausal women. A publication in the Journal of Ethnopharmacology documented icariin's binding to estrogen receptors potentially alleviating menopausal discomfort. The 24-month human bone trial included menopausal women without reporting hyperplasia, suggesting a safe estrogenic profile.

Biochanin A is an isoflavone found in red clover and chickpeas, metabolized in vivo to genistein. As a key constituent of red clover isoflavone preparations validated in meta-analysis (statistically significant −1.73 hot flushes/day), it contributes to the documented phytoestrogenic activity relevant to hot flash reduction.

Black cohosh (Cimicifuga racemosa) is the most extensively studied botanical for menopausal hot flashes. Multiple RCTs are documented in the NIH ODS fact sheet; it appears to act via serotonergic rather than estrogenic pathways. Evidence is mixed across trials but overall supports modest reductions in hot flash frequency and severity.

B. falcatum has been traditionally used for menopausal symptoms including hot flashes in East Asia. In a clinical trial, a decoction with B. falcatum as a major ingredient showed efficacy for relieving vasomotor symptoms in postmenopausal women. In vivo studies also confirm potent hypothermic effects.

At least two RCTs have tested Vitex specifically for hot flashes in peri- and postmenopausal women, with one finding significant reductions in frequency and severity versus placebo. A combination trial with St. John's wort found no significant difference from placebo. Evidence is mixed and the herb's phytoestrogenic and dopaminergic mechanisms provide partial mechanistic rationale.

Daidzein is a soy isoflavone metabolized to the more potent equol by gut flora in some individuals. Clinical trials, particularly in equol-producers, show reduction in vasomotor symptoms including hot flashes. Evidence is modest and population-dependent based on individual microbiome composition.

Clinical trials of soy isoflavones including daidzin-containing preparations have shown modest reductions in hot flash frequency in menopausal women, especially in equol-producing individuals. The Cochrane review found inconsistent overall evidence, while some individual RCTs demonstrated significant benefit.

A small clinical study (Yakoot et al., 2011) found that a herbal formula containing damiana improved menopausal symptoms including vasomotor symptoms. MSKCC acknowledges this evidence while noting confirmatory research is needed. Damiana's phytoestrogenic and anti-aromatase properties provide biological plausibility.

DHEA has been studied for vasomotor symptoms including hot flashes in postmenopausal women. Evidence is limited and inconsistent; oral DHEA is generally not considered effective enough to treat bothersome vasomotor symptoms as a standalone therapy. A Cochrane review found only uncertain evidence that DHEA decreases menopausal symptoms including hot flashes.

Evening primrose oil (EPO) contains gamma-linolenic acid (GLA) and has been used for menopausal hot flashes. A 2018 RCT showed EPO reduced hot flash severity; a 2021 RCT found it reduced night sweat frequency and severity but not hot flash frequency. Evidence is mixed but the ingredient is consistently studied and used for this indication.

Fennel-containing preparations have been tested in human RCTs for menopausal hot flashes. A fennel-valerian combination showed significantly reduced hot flash frequency and severity vs. placebo at 1–2 months. A standalone fennel RCT showed no significant difference over placebo, attributed to a high placebo response.

Standardized fenugreek seed extract has demonstrated significant reductions in hot flash frequency in menopausal women in multiple RCTs. One 90-day RCT with 1,000 mg/day reported a 47.8% decrease in hot flashes, with 32% of fenugreek-group women reporting complete resolution. The effect is attributed to fenugreek's phytoestrogenic activity increasing circulating estradiol.

Flaxseed is a rich source of the dietary lignan secoisolariciresinol diglucoside (SDG), metabolized to enterolignans with weak phytoestrogenic activity. Clinical trials for menopausal hot flashes show mixed results—smaller studies demonstrate benefit while a phase III NCCTG RCT did not confirm significant efficacy at 410 mg lignans/day.

Formononetin is a methoxylated isoflavone found primarily in red clover, serving as a metabolic precursor to daidzein. As a major constituent of red clover isoflavone preparations that have demonstrated statistically significant hot flash reductions in meta-analysis (−1.73/day vs. placebo), it contributes to the phytoestrogenic activity of clinically validated red clover extracts.

Japanese clinical trials beginning in the early 1960s demonstrated gamma oryzanol reduces hot flashes in menopausal and surgically postmenopausal women. In one study of 21 women given 300 mg/day for 38 days, more than 67% experienced a 50% or greater reduction in symptoms. The proposed mechanism involves suppression of LH secretion by the pituitary and stimulation of hypothalamic endorphin release.

Genistein is the predominant soy isoflavone and has the strongest individual clinical evidence for menopausal hot flashes. A 2-year double-blind RCT (n=389) showed a 56.4% reduction in mean hot flush frequency after 12 months of 54 mg/day genistein without adverse endometrial effects. Evidence is among the strongest for any single phytoestrogen.

A 2022 systematic review of 15 placebo-controlled RCTs found ginseng significantly reduced hot flash scores (SMD: −0.34, 95% CI: −0.66 to −0.01) and overall menopausal symptom burden in postmenopausal women. However, effects on hot flash frequency specifically, hormone levels, and endometrial thickness were not consistently demonstrated. Evidence quality is rated low to moderate due to risk of bias in the included studies.

GLA (via evening primrose oil) has been tested in multiple RCTs for menopausal hot flashes with some evidence of benefit. A randomized double-blind trial (n=56 menopausal women, BMJ 1994) found gamolenic acid from EPO significantly reduced daytime hot flush frequency. Subsequent trials and systematic review data support a modest but real effect on hot flush severity and frequency.

Soy isoflavones including glycitein reduce vasomotor symptoms (hot flashes) in menopausal women by acting as phytoestrogens at hypothalamic estrogen receptors. Meta-analytic evidence confirms that soy isoflavones improve hot flash frequency and severity in postmenopausal women. Glycitin is a constituent of the isoflavone preparations used in these trials.

A single-blind, parallel, dose-comparison human study in 22 postmenopausal women found that HMRlignan at 72 mg/day for 8 weeks reduced mean weekly hot flash frequency by 50% in the high-dose group. ENL levels increased substantially from baseline alongside this symptomatic improvement. No significant safety concerns were identified.

A single-blind, parallel, dose-comparison RCT in 22 postmenopausal women (36 mg/d or 72 mg/d for 8 weeks) showed statistically significant reductions in hot flash frequency, particularly at the higher dose. The higher dose produced roughly a 55% reduction in hot flashes at 4 weeks and a sustained ~50% reduction at 8 weeks. HMRlignan is rapidly absorbed and converted to enterolactone, a phytoestrogen that modulates estrogen receptor activity, providing a plausible mechanism.

Hops contains 8-prenylnaringenin (8-PN), considered the most potent phytoestrogen yet identified, which binds estrogen receptor-alpha. Multiple RCTs have tested standardized hop extracts for vasomotor symptom relief in menopausal women, with a 100 µg/day dose of 8-PN showing superiority to placebo at 6 weeks. Effects are modest and not always sustained at 12 weeks.

Isoflavones are a class of phytoestrogens (including genistein, daidzein, formononetin, biochanin A) found in soy, red clover, and kudzu, extensively studied in RCTs for menopausal hot flashes. Multiple systematic reviews support modest but statistically significant reductions in hot flash frequency, with efficacy modulated by individual equol-producer status.

Kudzu (Pueraria lobata) root is rich in isoflavones including puerarin, daidzin, and daidzein, with established phytoestrogenic activity. Memorial Sloan Kettering cites human evidence for hot flash and night sweat benefit attributed to its isoflavone content. An RCT of kudzu flower extract versus placebo was conducted in menopausal women.

A double-blind placebo-controlled RCT in 90 menopausal women found that 330 mg licorice extract three times daily for 8 weeks significantly reduced both the frequency and severity of hot flashes compared to placebo. Phytoestrogenic compounds in licorice are the proposed mechanism. This is one of the strongest single-herb clinical trials for a menopausal symptom.

Evidence for lignans in reducing hot flashes is mixed. Some earlier studies using flaxseed (21 mg lignans via 40 g/day) found efficacy comparable to conjugated estrogen for mild menopausal symptoms. However, a Phase III RCT (Mayo Clinic, NCCTG N08C7) using 410 mg lignans/day in postmenopausal women found no significant reduction versus placebo. A 2025 review found flaxseed lignans reduced perimenopausal symptoms overall.

Maca (Lepidium meyenii/peruvianum) is a Peruvian Andean root with long traditional use for reproductive and menopausal health. Multiple double-blind RCTs demonstrate significant reductions in vasomotor symptoms including hot flashes in peri- and postmenopausal women through non-estrogenic hormonal mechanisms.

A clinical study in 180 menopausal women found that a supplement containing magnolia bark, soy isoflavones, and lactobacilli more effectively reduced hot flash severity and frequency than the comparator. The 634-woman multicenter RCT found both control and magnolia-containing supplement groups experienced relief from vasomotor symptoms including hot flashes, though magnolia specifically enhanced psycho-affective rather than vasomotor outcomes.

Melatonin has been evaluated in clinical trials for menopausal hot flashes via GABAergic and thermoregulatory mechanisms. One double-blind RCT found 3 mg melatonin produced significant improvement in vasomotor symptoms in women with severe climacteric symptoms. A combination RCT (soy isoflavones + 8-prenylnaringenin + melatonin) also demonstrated improved hot flashes. Evidence is preliminary.

Gamma-oryzanol (γ-oryzanol), derived from Oryza sativa bran oil, has been used in Japan since the 1960s for menopausal hot flashes and is approved there for this indication. Multiple clinical studies show 67–85% of women experienced significant symptom reduction at 300 mg/day.

A randomized clinical trial (Fahami et al., 2010; PMC3203277) compared passionflower to St. John's wort in 59 menopausal women over six weeks. Both groups showed significant decreases in menopausal symptoms—including hot flashes, night sweats, insomnia, depression, and headaches—at weeks three and six (p<0.05). The proposed mechanism involves passionflower's GABAergic activity reducing central nervous system hyperexcitability associated with estrogen withdrawal, as menopause-related symptoms are partly linked to low GABA tone.

Paeonia lactiflora extract has demonstrated effects on menopausal hot flashes in animal models, acting on the hypothalamic-pituitary-gonadal axis, serotonergic pathways, and neuropeptide signaling. Clinical reviews suggest Chinese herbal formulas containing white peony have comparable effects to hormone therapy for menopause symptoms.

Phytoestrogens are a broad class of plant-derived compounds (isoflavones, lignans, coumestans) binding estrogen receptors, and are among the most studied non-hormonal approaches to menopausal hot flashes. Cochrane reviews and multiple systematic analyses confirm modest but statistically significant reductions in hot flash frequency versus placebo across multiple subclasses.

Progesterone alone or in combination with estrogen reduces vasomotor symptoms (hot flashes, night sweats) in perimenopausal and postmenopausal women. A PubMed-indexed RCT and clinical trial data confirm oral micronized progesterone cyclically given in perimenopause decreases hot flashes and improves associated sleep disruption.

Pycnogenol (French maritime pine bark extract) has been studied in multiple RCTs for menopausal symptoms including hot flashes. A double-blind RCT in 200 peri-menopausal women and a second trial in 38 women both demonstrated significant reductions in hot flash severity. Mechanism is non-hormonal, involving vascular relaxation via nitric oxide pathways.

Red clover (Trifolium pratense) isoflavones have been evaluated in multiple RCTs for menopausal hot flashes. A 2021 systematic review and meta-analysis of 8 trials found a statistically significant reduction of approximately 1.73 hot flashes per day versus placebo. Individual RCTs show reductions in hot flush frequency from the first month of supplementation.

Small human RCTs indicate resveratrol may reduce hot flash frequency and severity in perimenopausal and menopausal women through phytoestrogenic and vasodilatory mechanisms. A pilot randomized, placebo-controlled study in 80 perimenopausal women found 150 mg/day for 12 weeks reduced hot flash frequency by approximately 30% versus placebo. Evidence is preliminary due to small sample sizes.

The Rheum rhaponticum root extract ERr 731 has been tested in multiple RCTs and a 2-year clinical study for reduction of menopausal vasomotor symptoms including hot flashes. A 12-week double-blind RCT in 112 perimenopausal women showed significant reduction in hot flash frequency and severity versus placebo.

A 2019 RCT (Complementary Therapies in Clinical Practice) and an observational study (2024, Nutrients) both reported reductions in hot flash frequency and intensity with RJ supplementation in peri- and postmenopausal women. Phytoestrogenic activity of RJ provides a mechanistic rationale.

Sage (Salvia officinalis) has been evaluated in multiple clinical trials and a 2023 systematic review/meta-analysis, which found Salvia officinalis significantly reduces hot flash frequency in postmenopausal women. Traditional use in European folk medicine for hot flashes is also well-documented.

A 2016 randomized, double-blind, placebo-controlled trial (n=36 women aged 40–70) found that schisandra extract (BMO-30, ~392 mg/day) significantly reduced hot flashes, sweating, and palpitations versus placebo over 6 weeks, with continued improvement at 12 weeks (Kupperman Index and Menopause Rating Scale). A supportive mouse study using VCD-induced ovarian failure also demonstrated reduced tail skin temperature with schisandra treatment.

Secoisolariciresinol diglucoside (SDG) is the principal phytoestrogenic lignan of flaxseed, converted by gut bacteria to enterodiol and enterolactone. It has been directly studied in phase III RCTs for menopausal hot flashes. While a large NCCTG trial at 410 mg/day SDG did not show significant benefit versus placebo, smaller studies support its traditional phytoestrogenic use.

Sesame lignans are converted to enterolactone, a weak phytoestrogen that may reduce hot flash frequency by modulating thermoregulatory centers via estrogen receptor binding. The clinical study in 24 postmenopausal women using 50 mg sesame powder showed hormone status improvement, consistent with vasomotor symptom relevance. Evidence is preliminary and largely mechanism-based rather than from dedicated hot flash RCTs.

Multiple RCTs and meta-analyses demonstrate that soy isoflavones (genistein, daidzein) significantly reduce the frequency and severity of hot flashes in menopausal and perimenopausal women. A 2012 meta-analysis of 19 RCTs found isoflavones reduced hot flash frequency and severity by ~26% vs. placebo. Effects are real but modest compared to estradiol.

Soy isoflavones (primarily genistein and daidzein) have been studied in numerous RCTs for menopausal hot flashes with mixed but partially positive results. Several systematic reviews support modest efficacy, particularly in equol-producing individuals and those with higher baseline hot flash frequency. Classified as scientifically studied though not universally efficacious.

A systematic review and meta-analysis of 17–19 RCTs found soy isoflavones significantly reduced hot flash frequency by approximately 20% and severity by approximately 26% compared with placebo. Asian postmenopausal women, who consume substantially more dietary soy, have a markedly lower incidence of hot flashes than Western women. Evidence is clinically meaningful but effect sizes are moderate and heterogeneity across trials is high.

Multiple clinical studies, including a randomized double-blind placebo-controlled trial of 100 women, found SJW significantly reduced hot flash frequency, duration, and severity versus placebo by 8 weeks. NCCIH and Mayo Clinic acknowledge this as a small but consistent evidence base.

Ammonium succinate–based dietary supplements have been tested in multiple randomized, double-blind, placebo-controlled trials in perimenopausal and postmenopausal women and significantly reduced hot flushes. A pooled analysis of two RCTs (n=227) found significant alleviation of 16 of 21 menopausal symptoms on the Greene Climacteric Scale. Estradiol levels also increased significantly.

Valerian root (Valeriana officinalis) contains phytoestrogenic compounds and has been evaluated in a double-blind RCT of 68 menopausal women, showing significant reductions in hot flash severity and frequency versus placebo over 8 weeks. Evidence is preliminary but originates from a controlled clinical trial.

Multiple RCTs have tested vitamin E for menopausal vasomotor symptoms. A Mayo Clinic placebo-controlled crossover trial found vitamin E (800 IU/day) reduced hot flashes by approximately one per day versus placebo—statistically significant but clinically modest. A separate RCT in postmenopausal women found vitamin E (200 IU twice daily for 8 weeks) reduced hot flash frequency by roughly one-third.

Vitex agnus-castus (chaste tree) has been evaluated in RCTs for menopausal vasomotor symptoms including hot flashes. A 2025 systematic review confirms evidence from clinical studies that it modulates dopaminergic, phytoestrogenic, and serotonergic pathways; RCTs show improvements in hot flashes and vasomotor symptoms versus placebo.

Wild yam's diosgenin is a phytoestrogen that interacts weakly with estrogen receptors, forming the basis for its use against menopausal hot flashes. The only rigorous human trial — a double-blind, placebo-controlled crossover study of 23 menopausal women (Komesaroff et al., Climacteric 2001) — found no statistically significant reduction in hot flash frequency or severity versus placebo. Evidence is therefore scientific in design but negative in outcome; human benefit is unproven.

Anemarrhena is a key ingredient in the classic TCM formula Zhi Bai Di Huang Wan, prescribed for menopausal hot flashes and night sweats. It is traditionally understood to 'nourish Yin and clear empty heat,' the TCM mechanism underlying hot flashes. Well-documented traditional use across multiple centuries of East Asian clinical practice.

Borage oil is traditionally and widely used by women for hot flash reduction, attributed to GLA's prostaglandin-modulating effects. Clinical RCT evidence using the closely related GLA source evening primrose oil found no benefit over placebo for hot flash frequency or severity. No borage-oil-specific RCT for hot flashes exists in peer-reviewed literature.

DIM is widely used by practitioners and consumers to alleviate menopausal hot flashes on the basis that it favorably shifts estrogen metabolism. No published RCT has used hot flash frequency or severity as a primary endpoint for DIM specifically. The use is extrapolated from DIM's known effects on estrogen metabolite ratios.

Wild yam (Dioscorea villosa) is widely used in traditional and alternative medicine for menopausal hot flashes, leveraging its phytoestrogenic diosgenin content. However, the best-available clinical evidence—a double-blind, placebo-controlled trial in 23 post-menopausal women—found no significant reduction in hot flashes versus placebo.

Dong quai (Angelica sinensis) has been used for over 2,000 years in Traditional Chinese Medicine for menopausal complaints including hot flashes, typically in multi-herb formulas. Controlled clinical trials of dong quai used alone have not demonstrated significant hot flash improvement, placing evidence primarily in the traditional category.

Dong quai root (Angelica sinensis root) is the same medicinal material as Dong Quai—used for millennia in TCM in combination formulas for menopausal complaints including hot flashes. Solo-use RCTs have not demonstrated significant hot flash reduction, placing evidence in the traditional-use category.

Kava is used in herbal medicine for hot flashes associated with perimenopause, leveraging its anxiolytic and neurovegetative-stabilizing properties. Clinical trials in perimenopausal women demonstrated improvement in mood, anxiety, and general climacteric complaints, but hot flash frequency and severity were not significantly reduced as primary endpoints. The specific hot flash indication therefore rests on traditional herbal practice rather than direct clinical proof.

Motherwort has a long traditional use for menopausal hot flashes, particularly those accompanied by nervous tension and palpitations. The EMA mentions it for menopausal symptoms, and traditional European herbalism consistently recommends it for this indication. No dedicated clinical trials confirm efficacy specifically for hot flashes.

Pregnenolone is used traditionally as a precursor-hormone supplement for menopausal hot flashes, based on its ability to support downstream estrogen and progesterone production. Specific controlled clinical trial evidence for pregnenolone reducing hot flashes is lacking; the relationship is primarily mechanistic and traditional-practitioner-based.

Hot flashes are a core indication in TCM for Rehmannia, classified as heat manifestations of Yin deficiency. Prepared Rehmannia (Shu Di Huang) and raw Rehmannia are both used in classical menopausal formulas such as Zhi Bai Di Huang Wan and Er Xian Tang. TCM clinical practice over centuries has consistently applied Rehmannia to night sweats and hot flashes associated with kidney Yin deficiency.

Rehmannia is used traditionally and in formulated TCM preparations for menopausal hot flashes and night sweats. Catalpol may stimulate adrenal cortical hormones, offering a biological basis. A few studies confirm effectiveness in reducing night sweats and hormone disruptions when rehmannia is taken as part of multi-herb formulas.